ArticleWorld journal of hepatology2019

Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.

Katherine Kutney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.